

Eris Lifesciences (ERIS IN)

**Q1FY27 Result
Update**

July 30, 2026

☒ Estimate Change | ☒ Target | ☐ Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	BUY		BUY	
Target Price	1,700		1,750	
Sales (INR mn)	35,176	39,291	35,399	39,465
% Chng.	(0.6)	(0.4)		
EBITDA (INR mn)	12,327	14,225	12,938	14,537
% Chng.	(4.7)	(2.1)		
EPS (INR)	43.8	57.4	46.8	59.3
% Chng.	(6.4)	(3.2)		

Key Data

ERIS.BO | ERIS IN

BSE Code	540596
NSE Code	ERIS
52-W High / Low	INR 1,887 / INR 1,200
Face Value	1
Sensex / Nifty	77,655 / 24,250
Market Cap	INR 197 bn / \$ 2,065 mn
Shares Outstanding	138.58 mn
3M Avg. Daily Value	INR 170.12 mn

Shareholding Pattern (%)

Promoters	54.01
FIs	5.74
Mutual Funds	18.83
Domestic Institutions	1.84
Public & Others	19.58
Promoter's Pledge (INR bn)	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	1.4	8.3	6.2	(20.5)
Relative	0.2	8.0	12.9	(16.7)

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	28,936	31,294	35,176	39,291
EBITDA (INR mn)	10,172	11,201	12,327	14,225
Margin (%)	35.2	35.8	35.0	36.2
PAT (INR mn)	3,485	6,539	5,966	7,811
EV (INR mn)	219,898	216,139	211,347	205,054
Total Debt (INR mn)	24,217	23,097	17,597	10,597
C&C Eq. (INR mn)	2,228	673	(35)	(741)
EPS (INR)	25.6	48.1	43.9	57.4
Gr. (%)	(10.4)	87.6	(8.8)	30.9
DPS (INR)	7.4	-	8.0	8.0
Yield (%)	0.5	-	0.6	0.6
RoE (%)	12.8	19.4	14.4	16.5
RoCE (%)	13.2	14.6	15.2	18.2
EV/Sales (x)	7.6	6.9	6.0	5.2
EV/EBITDA (x)	21.6	19.3	17.1	14.4
PE (x)	55.6	29.6	32.5	24.8
P/BV (x)	6.8	5.0	4.4	3.8

Weak margins

Quick Pointers

- Bhopal commercialisation in August, ramp up largely by Q3FY27E
- GMs to bottom by 1HY27E, recovery from Q3

Eris Lifesciences' (ERIS) Q1FY27 EBITDA growth was muted at INR 2.9bn; up 7% YoY. We see improvement from H2FY27E/FY28E supported by the continued ramp-up of Semaglutide, Bhopal commercialization and growth in the insulin franchise. Swiss Parenterals remediation work is likely to keep growth subdued in the near term, with management guiding for neutral to low-single-digit growth and ~200bps margin pressure. We expect margins to recover in 2HFY27E as Bhopal ramps up, with gross margins likely to improve from Q3FY27. The company has multiple growth levers including insulin analogues, Semaglutide, new product launches and a structurally higher-growth biologics portfolio. Our FY27 and FY28E EPS stands cut by ~6%/3%. We maintain 'BUY' rating with revised TP of INR 1,700 (valuing at 17x EV/EBITDA on FY28E).

Revenue growth led by DBF segment: ERIS reported revenue growth of 13% YoY to INR 8.7bn, we est INR 8.4bn. Segment wise domestic formulations including Biocon business grew by 14% YoY aided by higher Semaglutide and Insulin sales. Swiss parenteral growth continues to remain muted at 6% YoY.

In line EBITDA; weak GMs: EBITDA came in at INR 2.9bn (up 7% YoY) in line with our est. OPM declined both YoY and QoQ by 188bps/224bps at 33.9%. Domestic business formulation margins stood at 35% vs 37% in Q4FY26. Swiss parental margins were at 27% vs 32% in Q4FY26. Overall GMs remained weak, down by 351bps YoY and 291bps QoQ given likely change in the product mix and higher solvent prices. Other expenses increased by 10% YoY. PBT was up 12% YoY. Tax rate stood at 20%. Resultant PAT came in at INR 1.4bn. EPS of INR 10.28/share.

Quarter Summary

Y/e Mar	Q1'27E	Q1'27A	% Var.	Q1'26A	YoY gr. (%)
Net Sales (INR mn)	8,465	8,733	3.0	7,730	13.0
EBITDA (INR mn)	3,023	2,962	-2.0	2,767	7.0
Margin (%)	35.7	33.9	-180 bps	35.8	-190 bps
PAT (INR mn)	1,469	1,424	-3.0	1,180	21.0

Source: Company, PL

Conference Call Highlights

Domestic branded formulation:

- Cardiac growth impacted by hypertension; expected to recover to market growth within 2 quarters.
- Two key cardiac products being revived; Esaxerenone launch expected in Aug'26.
- Diabetes underlying growth at 5–6%; Glimisave MV base effect to normalize shortly.
- Women's Health growing ahead of market; CNS expected to sustain market-beating growth.

Insulin:

- Insulin gaining market share; strong headroom from existing portfolio and analogues.
- Bhopal to commercialize in Aug'26, with ramp-up largely complete by end Q3FY27E.
- Semaglutide, degludec & degludec combo engineering batches completed; filings expected in Q2FY27E.
- Launch of Insulin Aspart in CY26; other analogues targeted for CY27.
- RHI cartridges faced stock-outs in Q1.
- GMs to remain stable in Q2FY27E, to improve from Q3FY27E and normalize by Q4FY27E with Bhopal ramp-up.

GLP-1:

- Semaglutide reached 20% volume / 14% value share in Q1FY27, its first quarter post-launch.
- Q2FY27E sales trends improving; Wegovy launch expected by end-July/August.
- Pricing is maintained. Initial supply constraints have eased with inventory build-up and manufacturing integration.

Exports:

- International business expected to remain flattish to low-single-digit growth in FY27E.
- Margins could face ~200–300bps pressure; clarity expected post-Q2FY27E.
- Freight and supply-chain disruptions continue to weigh on international operations.
- Swiss Parenterals growth impacted by facility remediation; revenue impact expected to be limited.
- International sites targeted to be audit-ready by December; long-term growth outlook remains intact.

Other highlights:

- Witnessed impact from higher solvent/ raw material costs.
- Q1FY27 Capex stood at INR 880 Mn.
- MR strength at ~4,000.
- Insulin GMs at 30–31%.

Exhibit 1: Quarterly Estimates

(INR Mn)	Q1FY27	YoY gr. (%)	Q2FY27E	YoY gr. (%)	Q3FY27E	YoY gr. (%)	Q4FY27E	YoY gr. (%)
Sales	8,733	13.0	8,772	10.7	8,907	10.3	8,764	15.8
EBITDA	2,962	7.1	3,081	6.9	3,247	15.3	3,037	11.0
Margin (%)	33.9		35.1		36.5		34.7	
Adj. PAT	1,424	20.7	1,504	25.2	1,614	37.9	1,424	(49.4)

Source: Company, PL

Exhibit 2: Q1FY27 Result Overview: In line EBITDA, Weak GMs

Y/e March (INR mn)	Q1FY27	Q1FY26	YoY gr. (%)	Q1FY27E	%Var	Q4FY26	QoQ gr. (%)	FY26	FY25	YoY gr. (%)
Net Sales	8,733	7,730	13.0	8,465	3.2	7,566	15.4	31,294	28,937	8.1
Raw Material	2,393	1,846	29.6	2,063	15.9	1,853	29.1	7,956	7,140	11.4
% of Net Sales	27.4	23.9		24.4		24.5		25.4	24.7	
Personnel Cost	1,534	1,444	6.2	1,589	(3.4)	1,369	12.1	5,568	5,051	10.2
% of Net Sales	17.6	18.7		18.8		18.1		17.8	17.5	
Others	1,844	1,672	10.2	1,789	3.0	1,609	14.6	6,569	6,574	(0.1)
% of Net Sales	21.1	21.6		21.1		21.3		21.0	22.7	
Total Expenditure	5,770	4,963	16.3	5,441	6.0	4,830	19.5	20,093	18,764	7.1
EBITDA	2,962	2,767	7.1	3,023	(2.0)	2,736	8.3	11,201	10,172	10.1
Margin (%)	33.9	35.8		35.7		36.2		35.8	35.2	
Depreciation	721	705	2.2	720	0.1	696	3.6	2,795	3,149	(11.2)
EBIT	2,242	2,062	8.7	2,303	(2.7)	2,040	9.9	8,406	7,024	19.7
Other Income	24	27	(11.2)	30	(20.3)	22	7.2	78	184	(57.8)
Interest	467	487	(4.2)	450	3.7	456	2.3	1,927	2,313	(16.7)
PBT	1,799	1,602	12.3	1,883	(4.5)	1,606	12.0	6,557	4,894	34.0
Total Taxes	362	360	0.5	414	(12.7)	(1,197)	(130.2)	(90)	1,144	(107.8)
ETR (%)	20.1	22.5		22.0		(74.5)		(1.4)	23.4	
Minority Income	13	62		-	#DIV/0!	(13)		279	228	
Reported PAT	1,424	1,180	20.7	1,469	(3.1)	2,816	(49.4)	6,368	3,522	80.8


Source: Company, PL

Exhibit 3: Semaglutide and Insulin sales aided higher DBF YoY

Segmental (INR Mn)	Q1FY27	Q4FY26	Q1FY26	YoY gr.	QoQ gr.	FY26	FY25	YoY gr.
DBF	8010	6710	7020	14%	19%	27770	25130	11%
Swiss Parentals	720	860	680	6%	-16%	3480	3240	7%
Others	-39.7	-47.1	15.6	-354%	-16%	-101	423	-124%
Total revenues	8,690	7,523	7,716	13%	16%	31149	28793	8%


Source: Company, PL

Exhibit 4: DBF showed higher growth YoY




Source: Company, PL

Exhibit 5: Change in product mix led to weak GMs YoY




Source: Company, PL

Exhibit 6: Lower GMs impacted EBITDA performance YoY



Source: Company, PL

Exhibit 7: Tax rate stood at 20% during the quarter



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	28,936	31,294	35,176	39,291
YoY gr. (%)	44.0	8.1	12.4	11.7
Cost of Goods Sold	7,140	7,956	9,497	10,216
Gross Profit	21,797	23,338	25,678	29,075
Margin (%)	75.3	74.6	73.0	74.0
Employee Cost	5,051	5,568	6,125	6,829
Other Expenses	6,574	6,569	7,226	8,021
EBITDA	10,172	11,201	12,327	14,225
YoY gr. (%)	50.7	10.1	10.1	15.4
Margin (%)	35.2	35.8	35.0	36.2
Depreciation and Amortization	3,155	2,795	2,923	3,051
EBIT	7,017	8,406	9,404	11,174
Margin (%)	24.3	26.9	26.7	28.4
Net Interest	2,313	1,927	1,619	975
Other Income	184	78	120	200
Profit Before Tax	4,888	6,557	7,905	10,399
Margin (%)	16.9	21.0	22.5	26.5
Total Tax	1,142	(90)	1,739	2,288
Effective Tax Rate (%)	23.4	(1.4)	22.0	22.0
Profit After Tax	3,746	6,647	6,166	8,111
Minority Interest	228	280	200	300
Share Profit from Associate	-	-	-	-
Adjusted PAT	3,485	6,539	5,966	7,811
YoY gr. (%)	(10.4)	87.6	(8.8)	30.9
Margin (%)	12.0	20.9	17.0	19.9
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	3,485	6,539	5,966	7,811
YoY gr. (%)	(10.4)	87.6	(8.8)	30.9
Margin (%)	12.0	20.9	17.0	19.9
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	3,485	6,539	5,966	7,811
Equity Shares O/s (mn)	136	136	136	136
EPS (INR)	25.6	48.1	43.9	57.4

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	52,933	54,536	57,036	59,536
Tangibles	52,930	54,536	57,036	59,536
Intangibles	3	-	-	-
Acc: Dep / Amortization	8,985	11,780	14,703	17,754
Tangibles	8,985	11,780	14,703	17,754
Intangibles	-	-	-	-
Net Fixed Assets	43,948	42,756	42,333	41,782
Tangibles	43,945	42,756	42,333	41,782
Intangibles	3	-	-	-
Capital Work In Progress	667	1,715	1,715	1,715
Goodwill	9,120	9,120	9,120	9,120
Non-Current Investments	105	100	100	100
Net Deferred Tax Assets	(2,294)	(622)	(622)	(622)
Other Non-Current Assets	857	1,622	1,622	1,622
Current Assets				
Investments	50	-	-	-
Inventories	3,348	4,368	4,819	5,382
Trade Receivables	4,586	6,803	7,228	8,073
Cash & Bank Balance	2,228	673	(35)	(741)
Other Current Assets	1,959	3,026	3,026	3,026
Total Assets	69,817	73,139	72,883	73,035
Equity				
Equity Share Capital	136	136	136	136
Other Equity	28,407	38,888	43,766	50,490
Total Network	28,543	39,024	43,902	50,626
Non-Current Liabilities				
Long Term Borrowings	17,375	9,558	4,058	(2,942)
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	6,842	13,539	13,539	13,539
Trade Payables	3,324	3,297	3,662	4,091
Other Current Liabilities	4,374	4,741	4,741	4,741
Total Equity & Liabilities	69,816	73,139	72,883	73,035

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	4,888	6,557	7,905	10,399
Add. Depreciation	3,155	2,795	2,923	3,051
Add. Interest	2,313	1,927	1,619	975
Less Financial Other Income	184	78	120	200
Add. Other	13	(197)	(520)	(520)
Op. Profit before WC Changes	10,369	11,082	11,927	13,905
Net Changes-WC	1,260	(4,580)	(509)	(981)
Direct Tax	(979)	(1,244)	(1,739)	(2,288)
Net Cash from Op. Activities	10,650	5,257	9,679	10,636
Capital Expenditures	(13,240)	(3,069)	(2,500)	(2,500)
Interest / Dividend Income	-	-	-	-
Others	12,440	120	100	20
Net Cash from Inv. Activities	(800)	(2,949)	(2,400)	(2,480)
Issue of Share Cap. / Premium	72	45	-	-
Debt Changes	(4,059)	(1,247)	(5,500)	(7,000)
Dividend Paid	(1,000)	-	(1,088)	(1,088)
Interest Paid	(1,451)	(1,933)	(1,619)	(975)
Others	(2,127)	(729)	220	200
Net Cash from Fin. Activities	(8,565)	(3,864)	(7,987)	(8,863)
Net Change in Cash	1,285	(1,556)	(708)	(706)
Free Cash Flow	(2,590)	2,189	7,179	8,136

Source: Company, PL

Quarterly Financials (INR mn)

Y/e Mar	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Net Revenues	7,924	8,075	7,566	8,733
YoY gr. (%)	10.1	8.9	4.0	23.8
Raw Material Expenses	2,024	2,233	1,853	2,393
Gross Profit	5,900	5,842	5,713	6,340
Margin (%)	74.5	72.3	75.5	72.6
EBITDA	2,882	2,816	2,736	2,962
YoY gr. (%)	15.3	6.4	9.3	17.4
Margin (%)	36.4	34.9	36.2	33.9
Depreciation / Depletion	691	703	696	721
EBIT	2,191	2,113	2,040	2,242
Margin (%)	27.7	26.2	27.0	25.7
Net Interest	496	488	456	467
Other Income	28	-	22	24
Profit before Tax	1,724	1,625	1,606	1,799
Margin (%)	21.8	20.1	21.2	20.6
Total Tax	382	365	(1,197)	362
Effective Tax Rate (%)	22.2	22.5	(74.5)	20.1
Profit After Tax	1,342	1,260	2,803	1,437
Minority Interest	143	91	(25)	9
Share Profit from Associate	(3)	(1)	12	4
Adjusted PAT	1,202	1,342	2,816	1,424
YoY gr. (%)	44.5	46.5	236.7	51.8
Margin (%)	15.2	16.6	37.2	16.3
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,202	1,342	2,816	1,424
YoY gr. (%)	44.5	46.5	236.7	51.8
Margin (%)	15.2	16.6	37.2	16.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,202	1,342	2,816	1,424
Avg. Shares O/s (mn)	138	138	138	138
EPS (INR)	8.7	7.2	20.4	10.3

Source: Company, PL


Key Financial Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	25.6	48.1	43.9	57.4
CEPS	48.8	68.6	65.4	79.9
BVPS	209.9	287.0	322.8	372.3
FCF	(19.0)	16.1	52.8	59.8
DPS	7.4	-	8.0	8.0
Return Ratio (%)				
RoCE	13.2	14.6	15.2	18.2
ROIC	10.4	11.6	12.9	15.1
RoE	12.8	19.4	14.4	16.5
Balance Sheet				
Net Debt : Equity (x)	0.8	0.6	0.4	0.2
Net Working Capital (Days)	58	92	87	87
Valuation (x)				
PER	55.6	29.6	32.4	24.8
P/B	6.7	4.9	4.4	3.8
P/CEPS	29.1	20.7	21.7	17.8
EV/EBITDA	21.6	19.2	17.1	14.4
EV/Sales	7.5	6.9	6.0	5.2
Dividend Yield (%)	0.5	-	0.5	0.5
FCFF Yield (%)	(1.4)	1.1	3.7	4.1
PEG Ratio	(5.4)	0.3	(3.8)	0.8

Source: Company, PL

Price Chart

(INR)


Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	09-Jul-26	BUY	1750	1416
2	21-May-26	BUY	1750	1458
3	09-Apr-26	BUY	1800	1354
4	16-Feb-26	BUY	1800	1414
5	08-Jan-26	BUY	1900	1553
6	13-Nov-25	BUY	1900	1575
7	08-Oct-25	BUY	1975	1590
8	06-Aug-25	BUY	1975	1808
9	08-Jul-25	BUY	1740	1734
10	20-May-25	BUY	1740	1444

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Ajanta Pharma	BUY	3400	3279
2	Anthem Biosciences	Buy	850	779
3	Apollo Hospitals Enterprise	BUY	9350	8754
4	Aster DM Healthcare	BUY	800	780
5	Aurobindo Pharma	HOLD	1400	1557
6	Brigade Enterprises	BUY	785	503
7	Cipla	Accumulate	1450	1393
8	Divi's Laboratories	Accumulate	6900	6755
9	Dr. Reddy's Laboratories	Accumulate	1300	1183
10	Eris Lifesciences	BUY	1750	1416
11	Fortis Healthcare	BUY	1120	944
12	Global Health	BUY	1450	1305
13	HealthCare Global Enterprises	BUY	820	635
14	Indoco Remedies	Hold	325	225
15	Ipca Laboratories	Buy	1800	1762
16	J.B. Chemicals & Pharmaceuticals	Buy	2400	2135
17	Jupiter Life Line Hospitals	BUY	1600	1444
18	Krishna Institute of Medical Sciences	BUY	800	806
19	Lupin	Accumulate	2500	2459
20	Max Healthcare Institute	BUY	1175	1085
21	Narayana Hrudayalaya	BUY	2250	1979
22	Oberoi Realty	Accumulate	2100	1883
23	Prestige Estates Projects	Buy	1800	1635
24	Rainbow Children's Medicare	BUY	1700	1431
25	Sun Pharmaceutical Industries	BUY	2070	1888
26	Sunteck Realty	BUY	520	291
27	Torrent Pharmaceuticals	BUY	5000	4866
28	Zydus Lifesciences	Accumulate	1080	1148

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Param Desai MBA Finance, Mr. Kushal Shah CFP, Passed CFA Level I Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Param Desai MBA Finance, Mr. Kushal Shah CFP, Passed CFA Level I Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.